ExodusPoint Capital Management LP Acquires 242,263 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

ExodusPoint Capital Management LP increased its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 440.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 297,234 shares of the company's stock after acquiring an additional 242,263 shares during the quarter. ExodusPoint Capital Management LP owned about 0.38% of Kura Oncology worth $2,589,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of KURA. Harbor Advisors LLC bought a new position in shares of Kura Oncology during the 4th quarter worth about $87,000. E Fund Management Co. Ltd. bought a new position in Kura Oncology during the fourth quarter valued at about $90,000. Corient Private Wealth LLC acquired a new position in Kura Oncology in the 4th quarter valued at approximately $109,000. Teacher Retirement System of Texas lifted its position in shares of Kura Oncology by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock worth $120,000 after acquiring an additional 2,285 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Kura Oncology in the 4th quarter worth approximately $127,000.

Insiders Place Their Bets

In other news, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares of the company's stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is currently owned by corporate insiders.

Kura Oncology Price Performance

Shares of KURA stock traded up $0.14 during trading hours on Friday, hitting $5.77. 2,111,548 shares of the company's stock were exchanged, compared to its average volume of 1,123,108. The stock's 50-day moving average is $7.36 and its 200-day moving average is $10.86. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology, Inc. has a 52 week low of $5.41 and a 52 week high of $23.48. The stock has a market cap of $465.96 million, a price-to-earnings ratio of -2.44 and a beta of 0.83.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. As a group, research analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on KURA shares. Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Kura Oncology in a research note on Tuesday. Scotiabank reduced their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. JMP Securities reissued a "market outperform" rating and issued a $28.00 price target on shares of Kura Oncology in a research report on Thursday, February 6th. StockNews.com raised Kura Oncology from a "hold" rating to a "buy" rating in a report on Friday, April 4th. Finally, BTIG Research cut Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $25.50.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.